0.70Open0.70Pre Close0 Volume185 Open Interest3.50Strike Price0.00Turnover53.81%IV0.72%PremiumDec 20, 2024Expiry Date0.67Intrinsic Value100Multiplier22DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.9208Delta0.2675Gamma5.96Leverage Ratio-0.0022Theta0.0019Rho5.49Eff Leverage0.0015Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet